Atrial Fibrillation, Stroke
Conditions
Brief summary
This is a prospective, single center, non-randomized study with two parallel arms intended to study if 4D Intracardiac echocardiography (4D-ICE) (Nuvision, Nuvera TM) will provide better visualization of the anatomical landmarks from the larger imaging volume and provide optimal intra procedural guidance similar to Transesophageal echocardiography (TEE) (GE 6VT-D ULTRASOUND TRANSDUCER) for Left atrial appendage closure (LAAC). The study will enroll approximately 52 subjects and will be followed through 12 months.
Detailed description
Standard intraprocedural guidance for transcatheter left atrial appendage closure (LAAC) employs a multi-modality integrated approach combining fluoroscopy for guiding the delivery system, and transesophageal echocardiography (TEE) for intracardiac characterization to guide device selection and monitor procedural complications. Successful implantation of the device is confirmed with contrast-enhanced fluoroscopy and color doppler flow imaging on TEE. TEE is the current gold standard for procedural guidance but requires general anesthesia (GA) to avoid patient motion and discomfort during the procedure. General anesthesia, however, is associated with pulmonary complications and patient discomfort due to endotracheal intubation. Intraprocedural LAAC guidance under local anesthesia or conscious sedation might help mitigate these GA-related disadvantages and has motivated multiple clinical studies, establishing intracardiac echocardiography (ICE) as a safe and feasible alternative to TEE. The new generation of NuVision ICE catheter offers a larger imaging volume of 90° x 90° with multiplanar reformatted (MPR) echo views for better visualization of anatomical landmarks and procedural guidance and aid in sizing of the device. This has a potential to improve outcomes and reduce procedure times while lowering healthcare costs. In this study, Role of NuVision Intracardiac Echocardiographic (ICE) catheter with Tranesopheal echocardiography (TEE) in predicting intra-procedural outcomes and success of implantation in patients undergoing left atrial appendage occlusion will be assessed.
Interventions
DEVICEImaging guidance with TEE and ICE for Left atrial appendage closure
The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
Sponsors
Kansas City Heart Rhythm Research Foundation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male/Females * Age:18-80 years * History of Atrial Fibrillation/Atrial flutter * Will have endocardial Left Atrial Appendage Closure (LAAC) with an Amplatzer Amulet or WATCHMAN FLX device
Exclusion criteria
* Inability or unwillingness of an individual to give written informed consent * Patient not following with our practice after the procedure * Complex anatomy for endocardial LAAC * Thrombus in LAA * Patients with pericardial effusion in pre-op TEE/CCTA * Patients currently pregnant (Serum beta HCG completed when labs obtained for the procedure are completed)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success of Implantation of Left Atrial Appendage Closure (LAAC) device | 1 Day | Success of Implantation of Amulet or Watchman FLX device |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraprocedural measurements | 1 Day | Transeptal access view, LAA thrombus, Stability of the device, Peri-device leaks, Device Repositioning, Clarity of mitral valve or pulmonary vein impingement will be noted as Yes/No from Echocardiogram |
| Intraprocedural measurements - LAA device size | 1 Day | LAA device size will be measured based on the LAA size |
| Location of the leaks | 1 Day | Location of the leaks will be identified |
Other
| Measure | Time frame | Description |
|---|---|---|
| Post Procedural Outcomes | 45 Days, 6 Months and 12 Months | Presence of any Peri-device leaks (PDL), Device Related Thrombus (DRTs), Micro migration and device tilt will be noted. |
| Post Procedural Outcomes - Size of the leaks | 45 Days, 6 Months and 12 Months | Leaks if any, leaks size will be measured |
Countries
United States
Contacts
Primary ContactDonita Atkins
Outcome results
None listed